Partial vs. sequential tests in WNL [Software]

posted by zan – US, 2014-07-01 20:03 (3947 d 12:35 ago) – Posting: # 13196
Views: 26,997

❝ I would not bother about #1–8 and rather con­cen­trate on

9. If ALL of the following criteria are met, it may not be necessary to

   include Group-by-Treatment in the statistical model:

● the clinical study takes place at one site;

● all study subjects have been recruited from the same enrollment pool,

● all of the subjects have similar demographics;

● all enrolled subjects are randomly assigned to treatment groups at study outset.

In this latter case, the appropriate statistical model need include only the factors Sequence, Period, Treatment, and Subject (nested within Sequence).


Hi Helmut,
On page 6 of the document (http://www.accessdata.fda.gov/drugsatfda_docs/anda/2008/077570Orig1s000BioeqR.pdf) we discussed above, reviewer provided the justification why the two dosing groups needed to be separated (looks stringent):

Although the subjects in the study were from the same geographic region and have the same demographic profiles, they were not enrolled in the study at the same time. The subjects enrolled in group 2 were screened after the beginning of the fasting study for group 1. There were 15 days in between the dosing of the two groups.
Therefore, individual statistical analysis is performed for each group.

zan

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,669 registered users;
36 visitors (0 registered, 36 guests [including 7 identified bots]).
Forum time: 08:38 CEST (Europe/Vienna)

The true Enlightenment thinker, the true rationalist,
never wants to talk anyone into anything.
No, he does not even want to convince;
all the time he is aware that he may be wrong.    Karl R. Popper

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5